So have they developed a vaccine, but they need money for trials, delivery..? How exactly would they go about and test if it works on humans? Are there people who volunteer to get infected with HIV?
Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
21–30 of 135 posts
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#22Earlier quoted context omitted.
The betterment of the world as a whole?
That's great, but the job of investors is to make money, not to better the world, isn't it?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#23Is the growth plan to raise the money from large donors (Gates foundation, Wellcome Trust, etc.) or to licence the technology to more traditional pharma firms ?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#24Does anyone know why this approach is "viewed as a rogue project by the immunology community"? Is it just because it's new, or is there something more fundamental that conflicts with established immunology?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#25Earlier quoted context omitted.
For human trials of this nature, typically at-risk populations can be used, and it's seen if there's a reduction in infection rates.
Exactly. In this case, we're lucky enough to use an amazing clinic set up in Durban, South Africa, which has a ~15% prevalence rate of HIV.
It seems like believing you are vaccinated would increase risky behaviour. This is bad in itself. It is also bad if the vaccine is only partially effective, since the risk effect might balance the vaccine effect.
With a placebo, knowing you only have a 50/50 chance of getting the actual trial vaccine might also help mitigate the risk effect.
Anyway, just wondering how all this works. Finding an effective vaccine would be fantastic; keep up the good work!
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#26Also, where's the science? Having something in the FAQ that states "We're awaiting publication in a peer-reviewed journal" is, to be blunt, pretty lame. Is the data and research open access? If not, why not?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#27Earlier quoted context omitted.
The betterment of the world as a whole?
That's great, but the job of investors is to make money, not to better the world, isn't it?
Seen through that lens, it's straightforward to see how enabling people to come up with innovative and effective new charities that startup investors can help fund is a worthwhile project.
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#28Given the high cost (hundreds of millions) of taking a vaccine through clinical trials, FDA approval and production I'm curious why the choice to go the non-profit route. Is the growth plan to raise the money from large donors (Gates foundation, Wellcome Trust, etc.) or to licence the technology to more traditional pharma firms ?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#29I'd like to understand why organisations like the Gates Foundation / NIH aren't excited by this approach? I'm assuming they've rejected this, which would explain the need to crowdfinance the next part. If they haven't rejected it, why aren't they being approached for grants? Also, where's the science? Having something in the FAQ that states "We're awaiting publication in a peer-reviewed journal" is, to be blunt, pret…
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#30Does anyone know why this approach is "viewed as a rogue project by the immunology community"? Is it just because it's new, or is there something more fundamental that conflicts with established immunology?
Hi all, this is Naveen from Immunity Project YC team. The fact that we are using ML to identify epitopes that are the preferred targets on the virus for HIV controllers is key to what makes our project unique. This is a newer approach for developing a vaccine and therefore makes it "rogue."